Bridgewater Associates LP Has $15.58 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Bridgewater Associates LP grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 54.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 135,186 shares of the company’s stock after buying an additional 47,638 shares during the period. Bridgewater Associates LP’s holdings in Neurocrine Biosciences were worth $15,576,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at about $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $32,000. EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. Finally, Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 1.0 %

NBIX opened at $126.59 on Thursday. The stock has a market capitalization of $12.82 billion, a price-to-earnings ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $110.81 and a twelve month high of $157.98. The company has a 50-day simple moving average of $118.97 and a 200 day simple moving average of $131.71.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Raymond James reaffirmed an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Barclays lowered their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.